Yuan Dan, Huang Yue, Cai Ying, Zhang Chi, Wang Jin-Jing, Zhou Jian-Guo
Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi, P.R.China.
Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, P.R.China.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251343487. doi: 10.1177/15330338251343487. Epub 2025 May 19.
IntroductionUterine sarcoma (US) is a rare tumor characterized by high aggressiveness, a tendency for recurrence and distant metastasis, and an extremely poor prognosis. In this study, we evaluated the expression of Orosomucoid 1 (ORM1) in different subtypes of US and the relationship between survival rates and clinicopathological features.MethodA retrospective study was conducted on 50 cases diagnosed with US in our hospital from 2011 to 2023. Immunohistochemistry (IHC) was used to detect the expression levels of ORM1 in different subtypes of US.The chi-square test and Kaplan-Meier survival analysis were used to analyze the relationship between ORM1 expression and clinical parameters as well as prognosis. Cox analysis was employed to evaluate the relationships between prognosis and clinical parameters in US.ResultCompared to normal proliferative endometrial tissue (NPE), the expression of ORM1 was downregulated in low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS) (P < .001,P < .001,and P < .001, respectively). Compared to normal uterine smooth muscle tissue (UNSM), the expression of ORM1 was upregulated in leiomyosarcoma (LMS) (P = .006). High ORM1 expression levels in US patients were associated with poor overall survival (OS) and progression-free survival (PFS) (P = .027 and P = .005, respectively). Multivariate COX analysis revealed that tumor stage and ORM1 expression are independent prognostic factors for US patients.ConclusionORM1 is expressed at low levels in ESS and at high levels in LMS. ORM1 potentially serve as a novel biomarker for the diagnosis, classification, and prognosis of US.
引言
子宫肉瘤（US）是一种罕见肿瘤，具有高侵袭性、复发和远处转移倾向，预后极差。在本研究中，我们评估了类粘蛋白1（ORM1）在不同亚型子宫肉瘤中的表达以及生存率与临床病理特征之间的关系。
方法
对2011年至2023年在我院诊断为子宫肉瘤的50例患者进行回顾性研究。采用免疫组织化学（IHC）检测子宫肉瘤不同亚型中ORM1的表达水平。采用卡方检验和Kaplan-Meier生存分析来分析ORM1表达与临床参数以及预后之间的关系。采用Cox分析评估子宫肉瘤预后与临床参数之间的关系。
结果
与正常增殖期子宫内膜组织（NPE）相比，低级别子宫内膜间质肉瘤（LG-ESS）、高级别子宫内膜间质肉瘤（HG-ESS）和未分化子宫肉瘤（UUS）中ORM1的表达下调（分别为P < 0.001、P < 0.001和P < 0.001）。与正常子宫平滑肌组织（UNSM）相比，平滑肌肉瘤（LMS）中ORM1的表达上调（P = 0.006）。子宫肉瘤患者中ORM1高表达水平与总生存期（OS）和无进展生存期（PFS）较差相关（分别为P = 0.027和P = 0.005）。多变量COX分析显示，肿瘤分期和ORM1表达是子宫肉瘤患者的独立预后因素。
结论
ORM1在子宫内膜间质肉瘤中低表达，在平滑肌肉瘤中高表达。ORM1有可能作为子宫肉瘤诊断、分类和预后的新型生物标志物。
